Shares of NuVasive, Inc. (NASDAQ:NUVA) have been given an average rating of “Hold” by the twenty-one ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $67.63.

NUVA has been the subject of a number of recent analyst reports. Royal Bank of Canada boosted their price objective on shares of NuVasive to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, November 27th. Robert W. Baird upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $60.00 to $82.00 in a report on Thursday, September 27th. ValuEngine lowered shares of NuVasive from a “buy” rating to a “hold” rating in a report on Thursday, November 1st. Cantor Fitzgerald restated a “hold” rating and issued a $58.00 price objective on shares of NuVasive in a report on Friday, October 19th. Finally, Morgan Stanley boosted their target price on shares of NuVasive from $55.00 to $77.00 and gave the company a “hold” rating in a research note on Tuesday, September 25th.

NASDAQ NUVA traded down $1.46 during mid-day trading on Thursday, reaching $57.86. The stock had a trading volume of 1,111,800 shares, compared to its average volume of 726,840. NuVasive has a 1 year low of $44.62 and a 1 year high of $72.41. The firm has a market cap of $3.05 billion, a P/E ratio of 30.29, a PEG ratio of 1.78 and a beta of 0.80. The company has a quick ratio of 1.83, a current ratio of 3.45 and a debt-to-equity ratio of 0.74.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Tuesday, October 30th. The medical device company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.06). NuVasive had a return on equity of 13.87% and a net margin of 2.24%. The firm had revenue of $271.30 million during the quarter, compared to analysts’ expectations of $265.70 million. During the same quarter in the previous year, the firm earned $0.52 earnings per share. NuVasive’s revenue was up 9.7% on a year-over-year basis. As a group, equities analysts expect that NuVasive will post 2.18 earnings per share for the current fiscal year.

In other NuVasive news, insider Matthew Link sold 2,582 shares of the business’s stock in a transaction on Monday, November 19th. The shares were sold at an average price of $62.02, for a total transaction of $160,135.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 8,671 shares of company stock valued at $538,741. Company insiders own 1.20% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of NuVasive by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,660,775 shares of the medical device company’s stock worth $330,822,000 after purchasing an additional 103,225 shares in the last quarter. Eagle Asset Management Inc. increased its stake in shares of NuVasive by 10.1% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,395,940 shares of the medical device company’s stock worth $99,083,000 after purchasing an additional 127,979 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of NuVasive by 10.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,303,103 shares of the medical device company’s stock worth $67,919,000 after purchasing an additional 121,467 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of NuVasive by 100.0% in the 3rd quarter. Victory Capital Management Inc. now owns 1,000,605 shares of the medical device company’s stock worth $71,023,000 after purchasing an additional 500,395 shares in the last quarter. Finally, Anchor Capital Advisors LLC increased its stake in shares of NuVasive by 1.2% in the 3rd quarter. Anchor Capital Advisors LLC now owns 996,179 shares of the medical device company’s stock worth $70,709,000 after purchasing an additional 12,202 shares in the last quarter.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Article: What is the float in trading stocks?

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.